

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
	10/692,605	10/24/2003	Gabriel Vogeli	28341/6276.NX1	8013	
	4743	4743 7590 07/15/2005		EXAMINER		
		MARSHALL, GERSTEIN & BORUN LLP			ULM, JOHN D	
	233 S. WACKER DRIVE, SUITE 6300 SEARS TOWER CHICAGO, IL 60606		00	ART UNIT	PAPER NUMBER	
				1649		

DATE MAILED: 07/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
		10/692,605	VOGELI ET AL.					
	Office Action Summary	Examiner	Art Unit					
	·	John D. Ulm	1649					
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status			•					
1)□ Re	esponsive to communication(s) filed on _	•						
		This action is non-final.						
	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition	of Claims							
4)⊠ Cla 4a) 5)□ Cla 6)□ Cla 7)□ Cla	4) Claim(s) 2 and 12-47 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected.							
Application	Papers							
	e specification is objected to by the Exam							
	e drawing(s) filed on is/are: a)							
	plicant may not request that any objection to	-,,	• •					
_	placement drawing sheet(s) including the core oath or declaration is objected to by the		· ·					
Priority under 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
Attachment(s)								
1) Notice of 8	References Cited (PTO-892) Draftsperson's Patent Drawing Review (PTO-948)		Date					
	on Disclosure Statement(s) (PTO-1449 or PTO/SB/ (s)/Mail Date	5) Notice of Informal F 6) Other:	Patent Application (PTO-152)					

Application/Control Number: 10/692,605

Art Unit: 1649

Restriction to one of the following inventions is required under 35 U.S.C. 121:

 Claims 2, 12 to 16 and 41 drawn to an isolated protein, classified in class 530, subclass 350.

- II. Claims 17 to 30, drawn to an isolated polynucleotide, vector, host cell, and method of use, classified in class 435, subclass 7.21.
- III. Claims 31 to 37, 39, 40 and 42, drawn to an antibody that binds to a receptor polypeptide, classified in class 530, subclass 388.22.
- IV. Claim 38, drawn to an anti-idiotypic antibody, classified in class 530, subclass 387.2.
- V. Claims 43 and 44, drawn to a method of treating by administering an antibody, classified in class 424, subclass 139.1.
- VI. Claims 45 to 48, drawn to a ligand binding assay, classified in class 436, subclass 501.

The inventions are distinct, each from the other because of the following reasons:

The protein of invention I, the nucleic acid of invention II, the antibody of invention III and the anti-idiotypic antibody of invention IV are four chemically and structurally different compounds each of which can be made and used without the others. These four different compounds do not reflect a common inventive concept because they lack a common utility that is based upon a common feature or combination of features that distinguish these four compounds as a group from the prior art.

Application/Control Number: 10/692,605

Art Unit: 1649

Inventions III and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody of invention III can be employed to detect its respective antigen in a sample or to isolate a protein comprising that antigen from a mixture of compounds, both of which are materially different from the method of treating that is invention V.

The isolated protein on invention I and the host cell of invention II are each related to the assay of invention VI as product and process of use. Because the isolated protein on invention I and the host cell of invention II are materially distinct for those reasons given above, a method that employs either of those products interchangeably is distinct therefrom.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Application/Control Number: 10/692,605

Art Unit: 1649

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (571) 272-0880. The examiner can normally be reached on 9:00AM to 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

GROUP 1800